Infineon Undervalued Former Chip Unit Qimonda by $1.88 Billion, Court Expert Says
By David Sachs
Infineon Technologies undervalued its defunct memory-chip business, Qimonda, by 1.72 billion euros ($1.88 billion) during its carve-out for a public listing, the German semiconductor company said, citing a court-appointed expert's decision in a legal dispute spanning 14 years.
Qimonda, a memory-chip company in which Infineon owned a majority stake, filed for insolvency in 2009, three years after its public listing. Insolvency administrator Michael Jaffe later sued Infineon in Munich district court, claiming that Qimonda was entitled to a reimbursement because Infineon omitted certain declarations during the carve-out.
Infineon said late Monday that the expert pegged Qimonda's foreign business at minus EUR1.045 billion and its domestic business at minus EUR72.3 million, but that the sum does not equate to a liability for Infineon.
"The submission of the opinion represents an interim step in the pending legal dispute," the company said. "The amount of potential liability of Infineon depends on other aspects."
Jaffe did not immediately respond to a request for comment.
Infineon said it is unclear when a decision by the court will be reached.
As of Sept. 30, Infineon said it has recognized EUR212 million in provisions related to the lawsuit with Qimonda.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 09, 2024 02:52 ET (07:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth